Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
PR Newswire•13/10/2026•07:00 ET
0
Key Highlights
- ➤Visara gains exclusive HT006.2.2 rights worldwide, excluding Greater China
- ➤Hiteck receives upfront, milestone payments and tiered net-sales royalties
- ➤Phase 1b highest-dose cohort achieved 50% complete corneal healing after eight weeks
- ➤HT006.2.2 will advance internationally as Visara’s VIS-102
- ➤Expansion study tests six-times-daily and three-times-daily eight-week regimens
Expert Statements
Ya Chen, Chairman of Hiteck
“Nerve growth factor has long been central to Hiteck's science, and HT006.2.2 represents the next generation of that work, designed for stability and everyday practicality at the ocular surface.”
Ya Chen, Chairman of Hiteck
“Visara's dedicated ophthalmology focus and global development capabilities make it a strong partner to advance this program internationally.”
Ya Chen, Chairman of Hiteck
“This agreement is an important step in Hiteck's international strategy, and we look forward to working closely with Visara as we continue development in Greater China.”
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China PR Newswire
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2
Get started
Create a free account to read the full story.